Posters/Publications

poster

Serum proteomic profiling reveals that the fatty acid synthase (FASN) inhibitor denifanstat provides metabolic benefits via increasing fibroblast growth factor 19 (FGF19) and decreasing 3-hydroxy-3-methylglutaryl-coa synthase 1 (HMGCS1) in NASH patients

AASLD The Liver Meeting

Date - 11/2022

paper

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Scientific Reports

Date - 09/2022

paper

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

Nature Communications

Date - 07/2022

poster

A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640 in NASH patients: results from the FASCINATE-1 study

EASL International Liver Congress

Date - 06/2022

poster

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640: efficacy, safety and biomarker results from a global phase 2 randomized pbo-controlled NASH trial, FASCINATE-1

Digestive Disease Week

Date - 05/2022

poster

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1)

NASH-TAG

Date - 01/2022

paper

Therapeutic efficacy of FASN inhibition in preclinical models of HCC

Hepatology

Date - 01/2022

oral

TVB-2640, a novel, first-in-class, fatty acid synthase (FASN) inhibitor: biomarker and metabolomic correlations with clinical MRI-PDFF response

NASH Summit

Date - 11/2021

oral

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1) conducted in the U.S. and China

AASLD The Liver Meeting

Date - 11/2021

oral

Translation of FASN Inhibitor TVB-2640 from Preclinical MOA to Clinical POC in NASH

NASH and Fibrosis Conference

Date - 09/2021

Posters/Publications

Serum proteomic profiling reveals that the fatty acid synthase (FASN) inhibitor denifanstat provides metabolic benefits via increasing fibroblast growth factor 19 (FGF19) and decreasing 3-hydroxy-3-methylglutaryl-coa synthase 1 (HMGCS1) in NASH patients

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640 in NASH patients: results from the FASCINATE-1 study

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640: efficacy, safety and biomarker results from a global phase 2 randomized pbo-controlled NASH trial, FASCINATE-1

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1)

Therapeutic efficacy of FASN inhibition in preclinical models of HCC

TVB-2640, a novel, first-in-class, fatty acid synthase (FASN) inhibitor: biomarker and metabolomic correlations with clinical MRI-PDFF response

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1) conducted in the U.S. and China

Translation of FASN Inhibitor TVB-2640 from Preclinical MOA to Clinical POC in NASH

Site map

Contact us